Kanishk Kumar – Hemophilia A Pipeline 2025: New Therapies Changing Patient Care
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, posted on LinkedIn:
“Hemophilia A Pipeline 2025: New Therapies Changing Patient Care
The Hemophilia A treatment landscape is evolving fast in 2025. Researchers and companies are pushing forward gene therapies, long-acting factor replacements, and innovative prophylactic options, all aimed at improving patients’ quality of life and reducing the burden of frequent treatments.
Recent Highlights:
On 10 October 2025, Roche initiated a Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NXT007 in patients with severe or moderate Hemophilia A.
On 08 October 2025, BioMarin Pharmaceutical Inc. announced a Phase III study to assess the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe Hemophilia A.
Key companies leading the way include Roche, Chugai Pharmaceutical Co., Ltd. , Shire , Pfizer , BioMarin Pharmaceutical Inc., Sinocelltech Ltd., Bayer, Ultragenyx , Spark Therapeutics, Inc., Octapharma, APCINTEX LIMITED , Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, Inc., CSL and others.”
See the full Hemophilia A Pipeline 2025 report and track the therapies shaping the future here.
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List